Ex vivo priming and long-term maintenance of anti-tumor T-cell lines are crucial for adoptive immunotherapy. We report here that CD40 activation of dendritic cells is necessary to activate CD8 lymphocytes ex vivo. IL-12 can substitute for this requirement and IL-7 greatly increases the CTL activity when used in combination with IL-12 or CD40L. We next successfully applied these findings to inducing acute myeloid leukemia-specific MHC class I-restricted CD8 T cells using CD8-enriched lymphocytes and dendritic cells obtained from HLA-matched allogeneic bone marrow transplantation donors and apoptotic leukemia blasts obtained from the BM recipients as the source of antigen. We found that CD4 T-cell help is important not only for inducing CD8 T cells, via CD40 ligation on dendritic cells, but also for establishing CD8 cells endowed with the property of self-renewal. Indeed we obtained, in all bulk cultures tested, after the second re-stimulation, effector cells displaying sizeable levels of cytotoxic activity towards recipient LB (range 20-50% at an effector target ratio of 10:1), but very low or absent reactivity against patient normal bone marrow cells (BMC) or patient PHA-blasts. LB-directed cytotoxic activity was maintained or augmented through repeated re-stimulation and effector cells showed a variable but continuos expansion. Phenotypic analysis demonstrates that the majority of effector cells were CD3+ (range 80-97%)/CD8+ (range 78-92%) lymphocytes. Cryopreservation of effector cells did not affect their cytotoxic activity. As this approach uses the whole diseased target cells, does not require definition of the target antigen, to select the most advantageous combination of antigen and available T-cell repertoire for each patients. Besides, since it allow the maintenance of a stable anti-leukemia T-cell response through repeated re-stimulation, we suggest that the approach is suitable for general application in adoptive immunotherapy. In the blood, two distinct subsets of DC have been characterized based on the lack of lineage markers such as CD14, CD19, CD3 and CD56 and the differential expression of the myeloid antigen CD11c. Myeloid DC (or DC1) express CD11c, CD13 and CD33, originate from myeloid bone marrow precursors, produce high levels of IL-12 when stimulated with CD40L and drive naive T-cell differentiation into Th1. Plasmacytoid monocytes, originally described in human lymph nodes based on their plasma cell-like morphology, have been isolated in the blood, express IL-3Ra and represent a functionally distinct dendritic cell-type, called DC2, which promotes the differentiation of Th2 cells. These cell are cross-regulatory in vitro, and the balance of these cells in vivo determines the character of cell-mediated immune and inflammatory responses. Thus, blood circulating DC subsets, DC1 and DC2, seem to play a key role in promoting anti-tumor immunity. Very few data exist on the relationship between leukemic cells and blood DC in leukemic patients. We and other groups reported previously that leukemic blasts from myeloid leukemia patients were able to differentiate into mature DC in vitro, while retaining their initial chromosomal abnormalities. Since the relationships between the various DC differentiation pathways and the hematopoietic progenitors remain unclear, blood circulating DC development might be affected by leukemic cell proliferation. In this study, we investigated whether circulating DCs could be isolated in the blood of patients with acute AML or CML. We show here that a dramatic quantitative imbalance in blood DC subsets is observed among a sample of 35 acute and chronic myeloid leukemias. Moreover, both DC1 and DC2 subsets were found to exhibit the original leukemic chromosomal abnormality suggesting their leukemic character. DC2 isolated from leukemic patients have impaired capacities of maturation: they could not acquire CD83, neither co-stimulatory molecules. Furthermore, we tested their stimulatory activity for allogeneic naïve T cells. Leukemic DC2 were found to have a diminished allostimulatory activity. These data suggest an impaired function of circulating DC subsets isolated from leukemic patients, which can strikingly influence on the type of immune response generated in vivo. Relapse after allogeneic stem cell transplantation can effectively be treated either with DLI alone or after remission induction with prior chemotherapy. Whereas remissions are frequently achieved in CML and to a lesser extent in patients with AML, myeloma, lymphoma, or MDS, remission rates in patients with ALL are short and long-term outcome is poor. We report on a patient who relapsed one year after HLA-identical, unrelated BMT for bcr/abl-positive cALL in CR2. After FLAG had failed to reinduce remission the patient received 3.5x108/kg unmobilized peripheral blood stem cells from the original bone marrow donor and was lost to follow-up for two months. Thereafter, the patient was readmitted to hospital because of extensive chronic GvHD (skin, mucosal and liver involvement), but in complete cytogenetic and molecular remission. Immunosuppression was initiated with CsA and low-dose MP (0.5 mg/kg) and ECPP (17x). GvHD slowly improved and after cessation of ECPP, immunosuppression was switched to MMF. The patient is now one year after DLI in continuous CR. A mHag-specific T-cell line was generated by stimulating the patient post-DLI (remission) cells with pretransplant monocytederived dendritic cells. The T-cell line lysed pretransplant PHA-blasts and bcr/abl-positive EBV-blasts, but not donor-derived PHA-S22
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Relapse after allogeneic stem cell transplantation can effectively be treated either with DLI alone or after remission induction with prior chemotherapy. Whereas remissions are frequently achieved in CML and to a lesser extent in patients with AML, myeloma, lymphoma, or MDS, remission rates in patients with ALL are short and long-term outcome is poor. We report on a patient who relapsed one year after HLA-identical, unrelated BMT for bcr/abl-positive cALL in CR2. After FLAG had failed to reinduce remission the patient received 3.5x108/kg unmobilized peripheral blood stem cells from the original bone marrow donor and was lost to follow-up for two months. Thereafter, the patient was readmitted to hospital because of extensive chronic GvHD (skin, mucosal and liver involvement), but in complete cytogenetic and molecular remission. Immunosuppression was initiated with CsA and low-dose MP (0.5 mg/kg) and ECPP (17x). GvHD slowly improved and after cessation of ECPP, immunosuppression was switched to MMF. The patient is now one year after DLI in continuous CR. A mHag-specific T-cell line was generated by stimulating the patient post-DLI (remission) cells with pretransplant monocytederived dendritic cells. The T-cell line lysed pretransplant PHA-blasts and bcr/abl-positive EBV-blasts, but not donor-derived PHA-or EBV-blasts. The T-cell line was positively selected for CD8+ cells and cloned by limiting dilution. Seven CD8+ T-cell clones were established showing an identical specificity pattern. The mHag recognized by these clones was restricted to HLA-A2.1, present in 71% of HLA-A2-positive individuals and expressed on hematopoietic cells, but not fibroblasts. Chromium release assays with synthetic peptides showed that only donor cells incubated with HA-1 were lysed by the T-cell clones whereas peptides derived from the bcr/abl fusion region specific for ALL were not recognized. The mHag HA-1 represents a nonapeptide with an allelic polymorphism differing in one single amino acid from the HA-1-negative allelic counterpart. It is expressed on cells of hematopoietic origin, including leukemic cells. This is the first evidence that HA-1-restricted GvL-effects after DLI are strong enough to eradicate full-blown, chemotherapyrefractory ALL relapse after allogeneic BMT.
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Minor Histocompatibility antigens (mHags) play a important role in the induction of donor derived cytotoxic T cells (CTLs) involved in the curative Graft-versus-Leukemia (GvL) reactivity. The GvL effect is often associated with the life-threatening Graftversus-Host-disease (GvHD), caused by ubiquitously expressed mHags. mHags with hematopoietic system restricted expression are therefore potential targets for cellular immunotherapy of relapsed leukemia. Functional studies with mHag HA-1 specific CTLs demonstrated that the mHag HA-1 is only expressed by cells of hematopoietic origin. Therefore the mHag HA-1 might be a potential target for cellular immunotherapy of relapsed leukemia with a low risk of GvHD. To ensure the feasibility and safety of such a mHag HA-1 specific therapy, we analysed the expression pattern of the HA-1 gene on the RNA level. We quantified the RNA expression levels of the mHag HA-1 in normal hematopoietic cells, in a variety of hematopoietic malignant cells and in various non-hematopoietic cells and tissues. Here we demonstrate the hematopoietic restricted expression of the mHag HA-1 gene at the transcriptional level with high RNA expression in normal and in a variety of malignant hematopoietic cells; no expression in non-hematopoietic cells and some tissues. Other tissues showed low HA-1 RNA expression which is caused by hematopoietic cell contamination as demonstrated by CD45 RNA expression. Thus, the mHag HA-1 is an excellent target antigen for cellular immunotherapy of hematological malignancies.
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Transfer of functional immune responses to aspergillus and CMV after haploidentical hematopoietic transplantation K. Perruccio, A. Tosti, S. Posati, A. Carotti, E. Burchielli, F. Aversa, M.F. Martelli, A. Velardi (Perugia, I) HLA haplotype-mismatched transplants are used for treatment of bad-risk leukemia patients lacking a matched donor. T cell depletion is obligatory as it prevents GvHD without need of post-grafting immune suppression, but carries the risk of leukemia relapse and infection. The HLA disparity triggers donor-vs-recipient NK cell alloreactions which control leukemia relapse without causing GvHD (Ruggeri, Blood 1999) . By contrast, the slow recovery of functional T cell immunity to pathogens is responsible for 35% infection-related mortality. Therefore, new strategies able to protect patients from infections, while not causing GvHD, are necessary. We addressed this problem by preparing large numbers of donor CD4+ T cell clones raised against whole (inactivated) Aspergillus fumigatus (Asp) and CMV. Clones are screened for cross-reactivity to host alloantigens by MLR. Nonhost-reactive clones, presumably devoid of GvHD potential, are pooled and infused into recipients at the dose of 5x105/Kg on day 15 after transplant. 10 patients received anti-Asp clones and 8 patients anti-Asp + anti-CMV clones. Results: 1) no patient developed GvHD, although no GvHD prophylaxis was given (note that 1-2 log less unmanipulated CD4+ cells cause severe GvHD). 2) genetically-marked antigen-specific T cells were readily detected in the circulation of patients up to 11 months after their infusion (time of last assessment). 3) whereas untreated patients developed Asp-and CMV-specific T cell responses in vitro later than 9 months post-transplant, all patients who had received such infusions exhibited high-frequency Asp-and CMVspecific responses within 3 weeks of the infusion, that is, 5 weeks post-grafting. 4) GM-CSF administration to patients promoted a remarkable increase in the frequency of the pathogen-specific T cells detected after the infusion (presumably, by improving APC function in vivo). 5) 10 of the 18 patients receiving anti-Asp cells had sinusitis and/or pneumonitis and positive Asp galactomannan antigenemia or documented Asp infections. 8 of these 10 patients improved clinically and/or cleared Asp antigenemia. 6) whereas 90% of the non-infused patients underwent continuous CMV reactivation for over 6 months postgrafting, the 8 patients who received anti-CMV clones remained CMV-negative. In conclusion, this procedure allows reliable discrimination of alloreactive of T cells, and the safe and effective transfer of functional immune cells across HLA barriers. DLI results in complete remission of relapsed CML after allogeneic stem cell transplantation (SCT) in 70-80% of the patients. To evaluate the hematopoiesis-specific mHag HA-1 and HA-2 as possible target antigens involved in this anti-leukemic effect, we studied the kinetics of HA-1 and HA-2 specific CD8+ T cells during the clinical response to DLI in an HLA-genotypically identical female donor-recipient pair with a genetic disparity for both HA-1 and HA-2. Hematopoietic cells including the leukemic cells from the patient expressed both HA-1 and HA-2 whereas the donor cells were negative for these polymorphic antigens. Tetrameric complexes were constructed consisting of HLA-A2 molecules and HA-1, or HA-2 peptides or the male specific control HY peptide derived from the SMCY gene. After informed consent, peripheral blood lymphocytes were isolated from the patient
